Future Perspectives of Antibody Manufacturing
|
|
- Horace Farmer
- 6 years ago
- Views:
Transcription
1 BioProduction 2005 Amsterdam Future Perspectives of Antibody Manufacturing John Birch Lonza Biologics
2 Monoclonal Antibodies A Success Story Fastest growing segment of the pharmaceutical market Sales forecast to increase from $5.4b in 2002 to $16.7b in licensed products (16 since 1997), several of which are blockbusters >150 in clinical trial, 15 identified in phase III 2 Of products in trial 42% are humanised and 28% fully human 1 PhRMA survey identifies MAbs as second largest biopharma category in development after vaccines - 76 out of 324 ( 23% ) Main therapeutic categories cancer and immunological 2 1. Reichert & Pavlou, Nature Reviews Drug Discovery,2004,3, Reichert et al. Nature Biotechnology 2005, 23, PhRMA 2004 survey. Medicines in Development, Biotechnology
3 Monoclonal Antibodies How Are They Made Licensed products all made in mammalian cell culture 10 produced in CHO 8 produced in lymphoid cells esp. NS0 and Sp2/0 Majority produced in batch / fed batch fermentation, some in perfusion Fermentation scales up to 20,000 litres Downstream based on chromatography Protein A used in majority of cases followed by two to three additional steps; ion exchange and sometimes HIC, size exclusion Virus removal / inactivation steps included
4 5000 Liter Process for Protein Production from Mammalian Cells Media Prep Depth Filtration Centrifuge Inoculum Grow-Up Kill System 50 Liter Fermenter 500 Liter Fermenter 5000 Liter Fermenter Utrafiltration 2-8º c Concentration / Diafiltration 0.2 µm Filtration 0.2 µm Filtration Protein A Affinity Intermediate Storage 0.2 / 0.45 µm IF Intermediate Filtration Holding Tank Concentration or Dilutiuon 2-8º c Anion Exchange 0.2 µm Filtration Concentration / Diafiltration 0.2 µm Filtration Final Filtration QC / QA Finished Goods Distributed to Customers
5 Monoclonal Antibodies The Quantities Frequently used at much higher doses than other biopharm proteins, leading to large volume demands 10s to 100s of kg per year and possibly tons in the future Predicted that demand will have increased to ca. 6 m.t. by from ca. 2 m.t. in 2004 Majority produced in batch / fed batch fermentation, some in perfusion Fermentation scales up to 20,000 litres 1. Gottschalk BioPharm International June 2005
6 20,000L Bioreactor & Add Tanks Portsmouth, New Hampshire
7 Portsmouth, NH, USA Large-Scale cgmp Production 60 miles from Boston s Airport 350,000 sq. ft. facility cgmp manufacture since x 2,000 l airlift 2 x 5,000 l airlift 2 x 1,500 l perfusion 3 x 20,000 l stirred 1 x 20,000 l stirred (2006)
8 Slough, England R&D and Small-Scale Production 10 miles Heathrow airport R&D facility incl. pilot plant cgmp manufacture : Disposable bioreactors 20 l to 400 l 2 x 200 l airlift 2 x 2,000 l airlift 500 l stirred ( 2006 )
9 Monoclonal Antibodies Upstream Progress Titres of 1 to 4 g/l now typical and 10g/l probably achievable Titres of 5.5 g/l (Lonza ) and 6.1 g/l (Abbott) reported for CHO, 5.1g/l for NS0 Improvements have come from two areas of development Improved culture conditions, including physicochemical conditions and particularly feeding strategies Improved expression technology Stringent selection strategies to isolate high producers ( typically rare events ) High throughput screening Systems which are independent of position in genome Improved cell lines
10 GS-CHO antibody titre improvements since old, titre = 0.04 g/l Viable cell conc n (10 6 /m L ) Antibody (g/l) new, titre = 5.5g/L Time (h) cells - old cells - new Ab - old Ab - new ( Birch, in Protein Production by Biotechnology, Elsevier 1990 )
11 Glutamine Synthetase (GS) Gene Expression System Expression vector encoding product gene(s) plus GS gene, allowing synthesis of glutamine an essential nutrient Only cells with GS gene (and hence product gene) survive Increase selection stringency - use weak promoter on GS gene - selects for rare integration into transcriptionally efficient sites in genome GS is inhibited by methionine sulphoximine (MSX) which can be used to increase stringency of selection Linked product gene driven by strong promoter (hcmv) to give high expression
12 Optimisation of a GS-CHO Process Optimised a CHOK1 process using GS expression technology to produce a monoclonal antibody ( cb72.3 ) Improved culture conditions especially feeds and physicochemical conditions Antibody genes transfected into improved variant of CHOK1 ( CHOK1SV ) New host (CHOK1SV ) grows spontaneously in suspension in chemically defined, protein free, medium without hydrolysates
13 Process Optimisation for a GS-CHO cell Line Process Original cell line Iteration 1 Iteration 2 New cell line (CHOK1SV) Iteration 3 Iteration 4 Iteration 5 New Clone Antibody (mg/l) Fold Increase
14 Growth comparison: Old vs. new GS-CHO cell lines growing in chemically defined medium 120 Viable cell concentration (10 5 /ml) H11 LB Time (h)
15 Protein-free chemically defined media Increasing emphasis from regulatory authorities on removal of animal-derived raw materials from antibody production processes Reduces risk of introducing adventitious agents and other contaminants Makes process optimization easier if ill defined additives such as serum and hydrolysates are avoided Cost benefits Reduces protein load in purification
16 Antibody purity by Coomassie Stained SDS PAGE analysis of In-Process Samples for a GS-CHO cell line Lane 1: Mol weight markers Lane 2: Inter assay control Lane 3: Cell culture supernatant Lane 4: Protein A eluate Main bands are antibody chains Minor bands are mostly host cell protein
17 Monoclonal Antibodies Upstream Progress Progress also being made in engineering cell lines to improve product characteristics e.g. glycoengineering to improve effector functions such as ADCC e.g. Glycart and Biowa Improved potency may reduce volumes required in the long term
18 Downstream Issues As upstream titres increase, downstream processing volumes increase in direct proportion to titre At current titres, buffer volumes can be an order of magnitude greater than upstream reactor Downstream becomes an increasing proportion of total costs; expensive chromatography steps including Protein A Growing interest in addressing downstream issues e.g More efficient chromatographic steps Fewer unit process steps Novel technologies e.g. membrane adsorbers
19 Buffer Hold Upper Level
20 Purification 2.0M and 1.4M Columns
21 Downstream Volumes for 2000l Fermenter Total Buffer Demand (L) 40,000 35,000 30,000 25,000 20,000 15,000 10,000 5,000 0 Effect of Fermentation Titre on Buffer Demand Fermentation Titre (g/l)
22 Where Next? Continued strong demand for monoclonal antibodies Mammalian cell culture processes likely to be important for forseeable future Continued improvements to the fermentation process Increased emphasis on improving host cell lines for improved productivity finding the bottlenecks downstream of transcription Use of knowledge from omics studies to inform process design and cell engineering Continuing improvements to media and feeds Improvements in downstream technology
23 Where Next? Increased emphasis on engineering cells to alter product properties such as glycosylation Reduction in product heterogeneity? Manufacturing efficiency will increasingly be a factor influencing the initial design of the product
24 Examples of Carbohydrate Profiles for IgGs prepared in NS0 and CHO cell lines Terminal %digal %monogal %agal %sialylated Sugars Cell Line NS NS CHO CHO Glycosylation can vary from cell line to cell line with respect to detailed profile NS0 cells also produce a low level of 1,3 gal-gal and N glycolyl neuraminic acid
25 Where Next? Other technologies, especially microbial, are likely to become more significant especially for antibody fragments 15 MAbs in phase III identified by Reichert including: 3 single chain fragments 3 Fab fragments Whole antibodies expressed in bacteria ( in non glycosylated form ) and in yeast and fungi. Increasing potential to engineer desired glycosylation characteristics into microorganisms Transgenic plants, animals and eggs at comparatively early stage and face similar downstream challenges as other systems
26 Summary Large scale manufacturing technology for MAbs has developed rapidly in recent years ( 100x increase in titres in ca. 15 years ) Improvements likely to continue based on further improvements to mammalian cell systems (cell lines and fermentation conditions) Downstream processing becoming an increasingly important area of focus for efficiency improvements Promise for other systems, especially microbial, in the longer term
APPROACHES TO IMPROVING THE PERFORMANCE OF MAMMALIAN CELL CULTURES FOR PROTEIN PRODUCTION
BioLOGIC USA BOSTON, 20 th OCTOBER 2004 APPROACHES TO IMPROVING THE PERFORMANCE OF MAMMALIAN CELL CULTURES FOR PROTEIN PRODUCTION Dr Robert Gay Lonza Biologics 2004 The Challenge of the MAb Market Global
More informationA Case Study on the Application of Disposable Technologies in cgmp Manufacturing Processes for a Therapeutic Antibody.
A Case Study on the Application of Disposable Technologies in cgmp Manufacturing Processes for a Therapeutic Antibody. Jeremy M Tong (presenting), Mark S Kettel, Edward M Perry, David J Pain, David M Valentine,
More informationRecombinant Antibody Production in Therapeutic Antibody Projects. Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016
Recombinant Antibody Production in Therapeutic Antibody Projects Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016 Presentation Outline 1 2 3 4 5 Introduction Recombinant Ab Production
More informationStrategies for the purification of high titre, high volume mammalian cell culture batches
Strategies for the purification of high titre, high volume mammalian cell culture batches Martin P. Smith. LONZA Biologics plc, 228 Bath Road, Slough, SL1 4DX. Presented at, Recovery & Purification. BioProcess
More informationRecent Developments & Future Directions in the Production of Monoclonal Antibodies. Rob Noel Plasma Product Biotechnology Conference 2009, Menorca
Recent Developments & Future Directions in the Production of Monoclonal Antibodies Rob Noel Plasma Product Biotechnology Conference 2009, Menorca Forecast sales by molecule type ($m), 2006 12 600,000 Pharmaceuticals
More informationGala s Gene Product Expression (GPEx ) Platform
Gala Biotech A Company with Gene Insertion and Manufacturing Technologies for the Next Generation of Gene Expression and Biologics Production Gala s Gene Product Expression (GPEx ) Platform Rapid creation
More informationManufacturing Integrated Biologics Manufacturing
Manufacturing Integrated Biologics Manufacturing Integrated Biologics Manufacturing Abzena provides customer focused process development and manufacturing services for cgmp and non-gmp production of recombinant
More informationSubject Index. chromatography step, 125-
A Alert limits, description, 70 Aluminum hydroxide based vaccine manufacture, start up and validation of sterile formulation and filling processes, 144-168 Anion-exchange chromatography step for clinical-grade
More informationAdvanced Microbial Protein Expression
Advanced Microbial Protein Expression Partners for Life Advancing tomorrow s medicines w A Biologics and Vaccines CDMO partner for your complete clinical journey Good science, experience and a quality
More informationMONOCLONAL ANTIBODIES AND BIOSIMILARS production, naming, pharmacovigilance and other pharmaceutical quality aspects
1 MONOCLONAL ANTIBODIES AND BIOSIMILARS production, naming, pharmacovigilance and other pharmaceutical quality aspects Prof. dr. Jos G.W. Kosterink Department of Clinical Pharmacy and Pharmacology University
More informationPRAXIS. A publication by Bioengineering AG
PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.
More informationPreclinical Development Drugs. Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015
Preclinical Development Drugs Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015 Product Development: Development process: File Approval Drug Discovery Preclinical Phase 1 Phase 2 Phase 3 Lifecycle
More informationFRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS
FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS Close-up of large scale UF/DF control unit conditions and
More informationImproving Bioprocessing Productivity Through the Application of Single-Use Protein A Columns
Improving Bioprocessing Productivity Through the Application of Single-Use Protein A Columns By K. John Morrow, Jr. Ph.D. In the last two decades, the bioprocessing industry has confronted the demands
More informationImplementation of a Micro Bioreactor System for Platform Cell Culture Process Development at Cobra Biologics
Implementation of a Micro Bioreactor System for Platform Cell Culture Process Development at Cobra Biologics Kristina Lae, Scientist, Cell Culture Cobra Biologics, Södertälje, Sweden Cobra Biologics and
More informationProteoGenix. Life Sciences Services and Products. From gene to biotherapeutics Target Validation to Lead optimisation
ProteoGenix Life Sciences Services and Products From gene to biotherapeutics Target Validation to Lead optimisation ProteoGenix Philippe FUNFROCK, founder and CEO French company located in Strasbourg,
More informationPharma&Biotech. XS Microbial Expression Technologies Optimize Productivity, Speed and Process Robustness
Pharma&Biotech XS Microbial Expression Technologies Optimize Productivity, Speed and Process Robustness Embracing Complexity Based on 30 years of innovation in microbial biotechnology, Lonza offers the
More informationTom Sulpizio and Jeff Taniguchi, Advanced Minerals Corporation A Member of Imerys 130 Castilian Way, Santa Barbara, CA 93117
ADVANCES IN DISPOSABLE DIATOMITE FILTER AID SYSTEMS FOR CGMP BIOSEPARATIONS Session Pretreatment in Bioseparations AFSS Annual Meeting Valley Forge, PA May 20, 2008 ABSTRACT Tom Sulpizio and Jeff Taniguchi,
More informationHollow Fiber Bioreactors: Single-Use. Perfusion. Scalable. Continuous Manufacturing.
Bioreactors and BioServices for the Life of your Proteins Hollow Fiber Bioreactors: Single-Use. Perfusion. Scalable. Continuous Manufacturing. Presented by: Scott Waniger Vice President, BioServices BPI
More informationTABLE OF CONTENTS. 1.3 Industry Pricing Trends Recent Industry Pricing Changes Contractor Utilization Rates 1-5
TABLE OF CONTENTS Chapter 1: EXECUTIVE SUMMARY 1.1 Introduction 1-1 1.2 Participants Locations 1-3 1.3 Industry Pricing Trends 1-4 1.3.1 Recent Industry Pricing Changes 1-4 1.3.2 Contractor Utilization
More informationEuropean Guideline for Virus Safety Evaluation of Clinical Trial Material
Plasma Product Biotechnology Meeting, May 8 12, 2007 European Guideline for Virus Safety Evaluation of Clinical Trial Material Dr. Hannelore Willkommen Vice President Regulatory Affairs, NewLab Bioquality
More informationThe Elite Provider. Cell & Gene. Therapy Manufacturing
The Elite Provider Cell & Gene Therapy Manufacturing GMP Manufacturing Services The cgmp manufacturing in Vigene is compliant with US FDA and EU EMA regulatory requirements. The manufacturing area consists
More informationTechnical Challenges in the Development of Biosimilars. E. Morrey Atkinson, PhD Interphex May 1, 2012
Technical Challenges in the Development of Biosimilars E. Morrey Atkinson, PhD Interphex May 1, 2012 FDA Guidance on Biosimilarity Guidance for Industry: Scientific Consideration in Demonstrating Biosimilarity
More informationThe Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives
The Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products CDER/FDA CASSS, Applications of
More informationBIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
More informationBIOTECHNOLOGY. Course Syllabus. Section A: Engineering Mathematics. Subject Code: BT. Course Structure. Engineering Mathematics. General Biotechnology
BIOTECHNOLOGY Subject Code: BT Course Structure Sections/Units Section A Section B Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Unit 7 Section C Section D Section E Topics Engineering Mathematics General
More informationDOWNSTREAM PROCESSING OF MONOCLONAL ANTIBODIES: CURRENT PRACTICES AND FUTURE OPPORTUNITIES. Brian Kelley, Greg Blank, and Ann Lee
1 DOWNSTREAM PROCESSING OF MONOCLONAL ANTIBODIES: CURRENT PRACTICES AND FUTURE OPPORTUNITIES Brian Kelley, Greg Blank, and Ann Lee 1.1 INTRODUCTION Monoclonal antibodies (mabs) are now established as the
More informationChapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More informationBiologics. Biologics. The Centre for Process Innovation. From innovation to commercialisation
Biologics Biologics The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The High Value Manufacturing Catapult is
More informationMicrobial Biotechnology agustin krisna wardani
Microbial Biotechnology agustin krisna wardani 1. The Structure of Microbes Microbes (microorganisms) are tiny organisms that are too small to be seen individually by the naked eye and must be viewed with
More informationJapanese Application Form: PMDA s Perspective on Manufacturing Process Description
Japanese Application Form: PMDA s Perspective on Manufacturing Process Description Reiko YANAGIHARA, Ph.D. Principal Reviewer Division of Pharmacopoeia and Standards for Drugs Office of Standards and Guideline
More informationExpectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective
Expectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective Christian Mayer AGES - Austrian Agency for Health and Food Safety Analytical Technologies Europe
More informationFrom gene to manufacturing: Application of efficient cell line development strategies to deliver reliable, high quality biomanufacturing processes
From gene to manufacturing: Application of efficient cell line development strategies to deliver reliable, high quality biomanufacturing processes Dr Alison Porter, FUJIFILM Diosynth Biotechnologies, UK
More informationBiosimilars Scientific Challenges and Implications
Biosimilars Scientific Challenges and Implications Professor Paul Declerck Laboratory for Therapeutic and Diagnostic Antibodies paul.declerck@pharm.kuleuven.be Biological medicinal product A well-defined
More informationThe validation of biological Active Pharmaceutical
This article presents a procedure for the validation of biological API manufacturing processes. It details each step of the procedure for biological processes applications, and covers the regulatory requirements
More informationStability of Biological Products
Stability of Biological Products Dr Jurgen Lindner Principal, BioPharma Consulting & Executive Secretary, APIMAA Biological Products Functional Proteins or Polypeptides (mab s, enzymes & inhibitors, growth
More informationADCC Reporter Bioassay: A Novel, Bioluminescent Cell-Based Assay for Quantifying Fc Effector Function of Antibodies
ADCC Reporter Bioassay: A Novel, Bioluminescent Cell-Based Assay for Quantifying Fc Effector Function of Antibodies Richard Somberg, Ph.D. October 2012 Outline Introduction to ADCC Problem with classic
More informationGuidance for Industry
Guidance for Industry Comparability Protocols - Protein Drug Products and Biological Products - Chemistry, Manufacturing, and Controls Information DRAFT GUIDANCE This guidance document is being distributed
More informationA complete single-use manufacturing process of monoclonal antibodies: a case study
A complete single-use manufacturing process of monoclonal antibodies: a case study Jakob Liderfelt, Janne Simola, Annika Forss, Gustav Rodrigo, Karin Torstensson, Tomas Björkman, Kjell Eriksson, Hans J
More informationDynamic High Capacity Mustang Q Membrane Units for Scaleable Anion Exchange Chromatography Purification of Adenoviral Vectors
Contact Us: www.pall.com/contact Dynamic High Capacity Mustang Q Membrane Units for Scaleable Anion Exchange Chromatography Purification of Adenoviral Vectors Dynamic High Capacity Mustang Q Membrane Units
More informationAdsorptive and Mechanical Mechanisms of Fluid Purification Using Charge Modified Depth Filtration Media. Dr. Robert Conway, Ph.D.
Adsorptive and Mechanical Mechanisms of Fluid Purification Using Charge Modified Depth Filtration Media Dr. Robert Conway, Ph.D. Depth Filter Cartridge Construction Zeta Plus Media Materials of Construction
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Veterinary Use CVMP/IWP/07/98-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES
More informationMagSi Beads. Magnetic Silica Beads for Life Science and Biotechnology study
MagSi Beads Magnetic Silica Beads for Life Science and Biotechnology study MagnaMedics Diagnostics B.V. / Rev. 9.2 / 2012 Wide range of products for numerous applications MagnaMedics separation solutions
More informationPurification of alpha-1 antitrypsin using an antibody based affinity chromatography medium
Purification of alpha-1 antitrypsin using an antibody based affinity chromatography medium Ulrika Meyer a, Hanna Wlad a, Sven Blokland b, Frank J.M. Detmers b and Henrik Ihre a a GE Healthcare Bio-Sciences
More informationMabSelect SuRe. GE Healthcare. Alkali-stabilized protein A-derived medium for capture of monoclonal antibodies. High stability in alkaline conditions
GE Healthcare Data File 11-11-65 AB Affinity chromatography MabSelect SuRe Alkali-stabilized protein A-derived medium for capture of monoclonal antibodies MabSelect SuRe (Superior Resistance) is a member
More informationOutsourcing and Partnering for Commercial Grade Manufacturing Frank Tufaro, Ph.D.
Outsourcing and Partnering for Commercial Grade Manufacturing Frank Tufaro, Ph.D. Should You Partner Manufacturing? $$$ versus Control 2 Ph. 1 Registration Trials Commercial Launch CMO CMO or Partner CMO
More informationFiltration of Cell Culture Growth Media and Process Buffers
Customer Application Brief Bioprocess, Biologicals, & Pharmaceutical Filtration of Cell Culture Growth Media and Process Buffers Introduction Media feeds and process buffers are two universal additives
More informationIntroduction to Protein Purification
Introduction to Protein Purification 1 Day 1) Introduction to Protein Purification. Input for Purification Protocol Development - Guidelines for Protein Purification Day 2) Sample Preparation before Chromatography
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
14 September 2017 EMA/CHMP/BWP/534898/2008 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the requirements for quality documentation concerning biological investigational medicinal
More informationGuideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics
Provisional Translation (as of April 19, 2013) PFSB/ELD Notification No. 0304007 March 4, 2009 To: Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food
More informationProSep Ultra Plus Chromatography Media
Data Sheet Data Sheet ProSep Ultra Plus Chromatography Media The highest dynamic binding capacity protein A affinity chromatography media, designed for cost effective, large-scale purification of today
More informationPerformance by Design: Engineering Functionality into Biopharmaceutical Products
Performance by Design: Engineering Functionality into Biopharmaceutical Products Susan Dana Jones, Ph.D. Cambridge Healthtech Institute Peptalk Overcoming Expression Challenges Session San Diego, CA January
More informationNEW! CHOgro Expression System
NEW! CHOgro Expression System At Mirus Bio, we know it s all about expression. Introducing the new CHOgro Expression System, a transient transfection platform that finally gets high protein titers with
More informationDriving Value through Innovation in Biotech Manufacturing. Agenda
Driving Value through Innovation in Biotech Manufacturing Jorg Thommes, PhD Senior Vice President Operations Technology and Innovation Biogen 7 October 2015 Agenda Biopharma Legacy, Trends, & Challenges
More informationReference Standards for Monoclonal Antibodies: Key Challenges Addressed
CASSS WCBP 2012: 16th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products January 23-25, 2012 Reference Standards for Monoclonal Antibodies: Key Challenges
More informationTrends in Perfusion Bioreactors: Will Perfusion Be the Next Revolution in Bioprocessing? June 15, 2011 BioProcess International
Trends in Perfusion Bioreactors: Will Perfusion Be the Next Revolution in Bioprocessing? June 15, 2011 BioProcess International Single-use/disposable bioprocessing equipment has come to thoroughly dominate
More informationDiscovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A
Discovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A Contacts: Marty Simonetti martysimonetti@gmail.com Kirby Alton kirby.alton@abeomecorp.com Rick Shimkets
More informationDownstream Processing in Biopharmaceuticals
Downstream Processing in Biopharmaceuticals Adoption of Disposable Technology at Improved Economies of Scale to Optimize Production Efficiency and Cost-effectiveness GBI Research Report Guidance GBI Research
More informationMass Spectrometry for Characterization of Monoclonal Antibodies: Regulatory Considerations
Mass Spectrometry for Characterization of Monoclonal Antibodies: Regulatory Considerations Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER Food and Drug Administration
More informationSynthetic Biology. Sustainable Energy. Therapeutics Industrial Enzymes. Agriculture. Accelerating Discoveries, Expanding Possibilities. Design.
Synthetic Biology Accelerating Discoveries, Expanding Possibilities Sustainable Energy Therapeutics Industrial Enzymes Agriculture Design Build Generate Solutions to Advance Synthetic Biology Research
More informationContinuous Processing Progress in Manufacturing
Cell World Conference, San Francisco, May 25-26 2017 Dr. Berthold Boedeker, Bayer AG, Biological Development Biologics at Bayer Regulatory support / drivers aof continuous processing Bayer s approach to
More informationAbstract. Materials and Methods. Introduction
The Performance of Serum-Free and Animal Component-Free Media for Multiple Hybridoma Cell Lines and Culture Systems Heather N. Loke, Steven C. Peppers, Daniel W. Allison, Damon L. Talley, and Matthew V.
More informationManufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective
Manufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective CASSS CMC Summer Forum 2017 Chris Storbeck, PhD Health Canada Outline Health Canada organization Regulation of
More informationPeptide libraries: applications, design options and considerations. Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST
Peptide libraries: applications, design options and considerations Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST Overview 1 2 3 4 5 Introduction Peptide library basics Peptide library design considerations
More informationPreparing the CMC section of IMPD for biological/biotechnology derived substances
Preparing the CMC section of IMPD for biological/biotechnology derived substances Your Logo Dr. Una Moore Health Products Regulatory Authority, Ireland Presented by Una Moore on 16 th April 2014. Health
More informationHigh Throughput Screening Technologies for developing purification processes of proteins. Michel Eppink, Synthon BV, Nijmegen
High Throughput Screening Technologies for developing purification processes of proteins Michel Eppink, Synthon BV, Nijmegen Introduction Overview From small to large processes New protein purification
More informationThe Development of a Bio-inspired, Chemically Defined Media Supplement for Cell Culture
The Development of a Bio-inspired, Chemically Defined Media Supplement for Cell Culture Justin Oliver*, Kirti Chaturvedi*, Damon Barbacci, Cindy Hunt, and Elizabeth Dodson BD Biosciences Advanced Bioprocessing,
More informationSimplicity is the key Continuous purification of monoclonal antibodies
Simplicity is the key Continuous purification of monoclonal antibodies L. Landric-Burtin Head of Downstream Processing Development, France Integrated Continuous Biomanufacturing Conference, Barcelona,
More informationLentiviral Vector Manufacturing Challenges and Solutions
Lentiviral Vector Manufacturing Challenges and Solutions Bo Kara Cell Gene Therapy CMC Elizabeth and Patience Save the Children clinic attendee Liberia Photo credit Martin Web/Save the Children Strategy:
More informationOptimization Strategies of Expression Cell Line Construction to Reduce the Biological Drug Development Risk. Feng Gao, MD, PhD. AutekBio CO.
Optimization Strategies of Expression Cell Line Construction to Reduce the Biological Drug Development Risk Feng Gao, MD, PhD AutekBio CO. Expression Systems used for Approved Antibody and Antibody-Related
More informationGlobal Leader in Viral Vector Technologies
Global Leader in Viral Vector Technologies Gene Therapy Vaccines - Discovery 1 SIRION BIOTECH ANY GENE TO ANY CELL Expert for viral vectors Competitive proprietary viral vector platforms High-end enabling
More informationBiopharmaceuticals - Current FDA & EMAs Regulations on glycan analysis
Biopharmaceuticals - Current FDA & EMAs Regulations on glycan analysis Jayesh Kattla, PhD March 2015 Gothenburg & Copenhagen 2013 Waters Corporation 1 Hope and Risk 2013 Waters Corporation 2 The total
More informationAnnex 4. Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology
Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology Replacement of Annex 3 of WHO Technical Report Series, No. 814 Introduction 177
More informationApplications involving the ViroCyt Virus Counter in the production of various recombinant proteins
Applications involving the ViroCyt Virus Counter in the production of various recombinant proteins Chris Kemp Kempbio, Inc. Frederick, MD USA chris.kemp@kempbioinc.com Presentation Summary Kempbio, Inc.
More informationComparability Assessment of BioTherapeutics: Paving the Way for Late-Stage Projects
Comparability Assessment of BioTherapeutics: Paving the Way for Late-Stage Projects Olga Friese, PhD Associate Research Fellow Pfizer Biotherapeutics PharmSci 28 January 2014 Overview Manufacturing process
More informationThe era of biological medicines
Chapter 1 The era of biological medicines Since their first use in the 1980s, biological medicines (including biosimilar medicines) have grown to become an indispensable tool in modern medicine. Worldwide,
More informationVirus Safety in Plasma- Derived Therapeutics: A Merck Perspective. IPFA Yogyakarta, March Louis Wong
Virus Safety in Plasma- Derived Therapeutics: A Merck Perspective IPFA Yogyakarta, March 2017 Louis Wong Associate director, Plasma Initiative, Asia-Pacific Content Regulatory Expectations for Plasma-Derived
More informationFiltration in Preparation of Cell Culture Media and Buffers
Filtration in Preparation of Cell Culture Media and Buffers Cell Culture Media and Buffers in Biopharmaceutical Production Cell culture media and process buffers are used in all biopharmaceutical operations.
More informationOperational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production
UCL Decisional Tools Research Operational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production Suzanne Farid PhD CEng FIChemE Reader (Associate
More informationJ. Fraser Wright, Ph.D.
Towards Better Characterization of Recombinant AAV Gene Transfer Vectors: Case Studies Illustrating Challenges with Dose Determining Vector Concentration methods J. Fraser Wright, Ph.D. Well Characterized
More informationRegulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products
Regulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products Xiaobin Victor Lu Product Reviewer Gene Therapies Branch DCGT/OCTGT/CBER/FDA MEASUREMENT
More informationThe Use of Disposable Technologies in Antibody Manufacturing Processes
The Use of Disposable Technologies in Antibody Manufacturing Processes Tim Matthews and Brad Wolk Process Development Engineering Genentech, Inc. South San Francisco, CA Outline Rationale for using disposable
More informationCHOgro Expression System
SDS and Certificate of Analysis available at mirusbio.com/6260 INTRODUCTION The CHOgro Expression System is an optimized platform for transient, high titer protein production in suspension CHO derived
More informationCritical Analytical Measurements for Bioreactor Optimization. controlling an organism s chemical environment leads to consistent and
Critical Analytical Measurements for Bioreactor Optimization Mettler-Toledo Ingold, Inc., Bedford, MA Abstract Most bioreactor processes share a basic principle; optimizing and controlling an organism
More informationBalanCD HEK293 SYSTEM
BalanCD HEK293 SYSTEM Maximize productivity in suspension cultures Versatile formulation supports transfection and production including: - Rapid, scalable production of viral vectors - Use the same system
More informationAn effective platform for purification of IgM monoclonal antibodies using Hydroxyapatite
An effective platform for purification of IgM monoclonal antibodies using Hydroxyapatite Frank Hensel, Patrys, GmbH Pete Gagnon, Validated Biosystems 5th International Conference on Hydroxyapatite and
More informationRequirements for demonstrating biosimilarity of monoclonal antibodies
Requirements for demonstrating biosimilarity of monoclonal antibodies Dr. Steffen Gross Section Mono-/Polyclonal Antibodies Paul-Ehrlich-Institut Germany http://www.pei.de Outline Biosimilars Regulatory
More informationPurification of mfp. from an Overnight Culture. Laboratory 17
Purification of mfp from an Overnight Culture When scientists at a therapeutics company, like Amgen, have successfully identified a promising therapeutic protein, two objectives would be to locate and
More informationGuideline on requirements for the production and control of immunological veterinary medicinal products
14 June 2012 EMA/CVMP/IWP/206555/2010 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on requirements for the production and control of immunological veterinary Draft agreed by Immunologicals
More informationOverview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services
Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations Audrey Chang, PhD, Senior Director Development Services Definition of Biologics: PHS Act, section 351 Virus, therapeutic
More informationRegulatory Review Considerations of Drug-Linker Quality in ADCs
Regulatory Review Considerations of Drug-Linker Quality in ADCs Xiao Hong Chen, Ph.D. Acting Quality Assessment Lead Division of New Drug Products I, Branch II ONDP/OPQ/CDER/FDA Outlines ADC IND submissions
More informationLabChip GXII: Antibody Analysis
WHITE PAPER LabChip GXII: Antibody Analysis Antibody Analysis using microfluidic technology in high throughput Quality by Design Experiments Abstract Current initiatives in Process Analytical Technology
More informationCritical Quality Attributes for Live Viral Vaccines. Mark S. Galinski Vaccine Analytical Sciences, MedImmune, Mountain View, CA USA
Critical Quality Attributes for Live Viral Vaccines Mark S. Galinski Vaccine Analytical Sciences, MedImmune, Mountain View, CA USA Terminology Quality Release Standards The specifications and procedures
More informationMabSelect PrismA. gelifesciences.com/bioprocess
is a next-generation Protein A chromatography resin that offers significantly enhanced alkaline stability and binding capacity for improved process economy in monoclonal antibody (mab) processing. The
More informationProtein Sources (Heterologous expression of proteins)
Protein Sources (Heterologous expression of proteins) Adrian Suarez Covarrubias Before starting out - why? what? when? where? Recombinant expression? if so, choice of host: prokaryote? eukaryote? modification
More informationCharacterization of Biotechnology Products: A Regulatory Perspective
Characterization of Biotechnology Products: A Regulatory Perspective Laurie Graham Acting Team Leader FDA/CDER/OPS/OBP Division of Monoclonal Antibodies WCBP 2013 1 Disclaimer The views and opinions expressed
More informationSpecial Additional Papers for B.Sc. (Hons.)Biotechnology Transcriptomics and Metabolomics (306) M.M.-100 Transcriptomics and Metabolomics Cloning and expression of heterologous genes: Redirecting metabolic
More informationThe practical task of monoclonal IgG purification with CHT TM ceramic hydroxyapatite
The practical task of monoclonal IgG purification with CHT TM ceramic hydroxyapatite Pete Gagnon, Jie He, Paul Ng, Julia Zhen, Cheryl Aberin, Heather Mekosh 11th Annual Waterside Conference, Chicago, May
More informationFast Trak Services: a collaborative project to accelerate downstream biosimilar process development
GE Healthcare Fast Trak Services: a collaborative project to accelerate downstream biosimilar process development A case study Case study, 2924332 AA Fast Trak Services A collaborative project to accelerate
More informationTable of Contents. Presented by
Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com May 2017 TABLE OF CONTENTS
More information